Contraindications: Not for use in individuals with known or suspected androgen-sensitive malignancy, active hepatic impairment, uncontrolled cardiovascular disease, or hypersensitivity to Nandrolone or sesame/arachis carrier oils. Contraindicated in women of childbearing potential due to virilisation risk and teratogenicity. Not intended for individuals under 21 years of age.
Side Effects: Nandrolone Decanoate suppresses endogenous testosterone production; symptoms of androgen deficiency (low libido, fatigue, mood changes) may emerge without a co-administered testosterone base. Prolactin elevation — a characteristic of 19-nor compounds — can cause galactorrhoea or sexual dysfunction at higher doses. Haematocrit rise, HDL reduction, and acne are possible; androgenic effects are lower than testosterone but not absent.
Monitoring: Obtain baseline and mid-cycle bloodwork (weeks 6–8) including prolactin, LH, FSH, total testosterone, oestradiol, haematocrit, and a lipid panel. Blood pressure should be self-monitored weekly. Any nipple sensitivity, persistent headache, or significant mood alteration warrants early panel review.
PCT: Post-cycle therapy with a SERM (Nolvadex 40/40/20/20 mg or Clomid 50/50/25/25 mg over four weeks) should begin approximately three weeks after the final Decabolin injection, aligned with Nandrolone clearance. For beginners, a structured PCT plan should be sourced and on hand before the first injection day.